Education
About Us
Working with TipRanks
Follow Us
Transcenta Holding Limited (HK:6628)
:6628
RESEARCH TOOLSreports
6628 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$0.50 - HK$2.22
Previous CloseN/A
Volume339.50K
Average Volume (3M)1.14M
Market Cap
HK$610.93M
Enterprise ValueHK$640.13M
Total Cash (Recent Filing)HK$169.42M
Total Debt (Recent Filing)¥250.61M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Sep 02, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding437,361,940
10 Day Avg. Volume990,254
30 Day Avg. Volume1,137,692
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Transcenta Holding Limited News
PremiumCompany Announcements
Transcenta Holding Limited Announces Successful AGM Outcomes
PremiumCompany Announcements
Transcenta Unveils Promising Osemitamab Trial Results at ASCO 2025
PremiumCompany Announcements
Transcenta Holding Limited Schedules 2025 Annual General Meeting
PremiumCompany Announcements
Transcenta Unveils Promising Preclinical Results for Novel Cancer TherapyPremiumCompany Announcements
Transcenta Grants Award Shares to Employees Under Incentive Scheme
PremiumCompany Announcements
Transcenta Clarifies Annual Results Announcement
PremiumCompany Announcements
Transcenta Reports 2024 Financial Results with Strategic R&D Reprioritization
6628 FAQ
What was Transcenta Holding Limited’s price range in the past 12 months?
Transcenta Holding Limited lowest stock price was HK$0.50 and its highest was HK$2.22 in the past 12 months.
What is Transcenta Holding Limited’s market cap?
Transcenta Holding Limited’s market cap is HK$610.93M.
When is Transcenta Holding Limited’s upcoming earnings report date?
Transcenta Holding Limited’s upcoming earnings report date is Sep 02, 2025 which is in 69 days.
How were Transcenta Holding Limited’s earnings last quarter?
Transcenta Holding Limited released its earnings results on Mar 28, 2025. The company reported -HK$0.418 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.418.
Is Transcenta Holding Limited overvalued?
According to Wall Street analysts Transcenta Holding Limited’s price is currently Overvalued.
Does Transcenta Holding Limited pay dividends?
Transcenta Holding Limited does not currently pay dividends.
What is Transcenta Holding Limited’s EPS estimate?
Transcenta Holding Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transcenta Holding Limited have?
Transcenta Holding Limited has 437,361,940 shares outstanding.
What happened to Transcenta Holding Limited’s price movement after its last earnings report?
Transcenta Holding Limited reported an EPS of -HK$0.418 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.622%.
Which hedge fund is a major shareholder of Transcenta Holding Limited?
Currently, no hedge funds are holding shares in HK:6628
Transcenta Holding Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.62%
12-Months-Change
Fundamentals
Return on Equity
-32.59%
Trailing 12-Months
Asset Growth
-31.48%
Trailing 12-Months
Company Description
Transcenta Holding Limited
Transcenta Holding Limited (6628) is a biopharmaceutical company engaged in the discovery, development, and manufacturing of innovative biologics. The company operates within the healthcare sector, focusing on oncology, bone and kidney diseases, and other unmet medical needs. Transcenta leverages its integrated technology platforms to advance its pipeline of therapeutic candidates and aims to provide accessible and affordable treatments to patients globally.
Technical Analysis
SinoMab Bioscience Ltd.
―
Sirnaomics Ltd.
―
Clover Biopharmaceuticals Ltd.
―
TOT BIOPHARM International Co. Ltd.
―
Kintor Pharmaceutical Ltd
―